The Experience of a Tertiary Reference Hospital in the Study of Rare Neurological Diseases

Author:

Sintila Styliani-Aggeliki1,Boziki Marina1ORCID,Bakirtzis Christos1ORCID,Stardeli Thomai1,Smyrni Nikoletta1,Nikolaidis Ioannis1ORCID,Parissis Dimitrios1,Afrantou Theodora1ORCID,Karapanayiotides Theodore1ORCID,Koutroulou Ioanna1,Giantzi Virginia1,Theotokis Paschalis2ORCID,Kesidou Evangelia2,Xiromerisiou Georgia3ORCID,Dardiotis Efthimios3ORCID,Ioannidis Panagiotis1ORCID,Grigoriadis Nikolaos1ORCID

Affiliation:

1. 2nd Department of Neurology, AHEPA University Hospital, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece

2. Laboratory of Experimental Neurology and Neuroimmunology, 2nd Department of Neurology, AHEPA University Hospital, 54636 Thessaloniki, Greece

3. Department of Neurology, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece

Abstract

Background and Objectives: Rare diseases (RDs) are life-threatening or chronically impairing conditions that affect about 6% of the world’s population. RDs are often called ‘orphan’ diseases, since people suffering from them attract little support from national health systems. Aim: The aim of this study is to describe the clinical characteristics of, and the available laboratory examinations for, patients who were hospitalized in a tertiary referral center and finally received a diagnosis associated with a Rare Neurological Disease (RND). Materials and Methods: Patients that were hospitalized in our clinic from 1 January 2014 to 31 March 2022 and were finally diagnosed with an RND were consecutively included. The RND classification was performed according to the ORPHAcode system. Results: A total of 342 out of 11.850 (2.9%) adult patients admitted to our department during this period received a diagnosis associated with an RND. The most common diagnosis (N = 80, 23%) involved an RND presenting with dementia, followed by a motor neuron disease spectrum disorder (N = 64, 18.7%). Family history indicative of an RND was present in only 21 patients (6.1%). Fifty-five (16%) people had previously been misdiagnosed with another neurological condition. The mean time delay between disease onset and diagnosis was 4.24 ± 0.41 years. Conclusions: Our data indicate that a broad spectrum of RNDs may reach a tertiary Neurological Center after a significant delay. Moreover, our data underline the need for a network of reference centers, both at a national and international level, expected to support research on the diagnosis and treatment of RND.

Funder

Genesis Pharma

Institute of Applied Biosciences at the Centre for Research and Technology Hellas

Publisher

MDPI AG

Subject

General Medicine

Reference35 articles.

1. Criteria to define rare diseases and orphan drugs: A systematic review protocol;Abozaid;BMJ Open.,2022

2. The Lancet Neurology (2017). Rare advances for rare diseases. Lancet Neurol., 16, 1.

3. Authorization and reimbursement of orphan drugs in an international comparison;Roll;Gesundheitswesen,2011

4. (2022, September 01). Orphanet. Available online: https://www.orpha.net.

5. (2022, September 01). European Reference Networks. Available online: http://www.ern-rnd.eu.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3